Dry powder formulation of azole derivative for inhalation

US11103501B2 · kind B2 · utility

Inventors

• Arthur Deboeck · Gurabo, US
• Francis Vanderbist · Sint-Genesius-Rode, BE
• Philippe Baudier · Waterloo, BE
• Thami Sebti · Braine-le-Comte, BE
• Christophe Duret · Quintal, FR
• Karim Amighi · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BE

Key dates

• Filing date: Oct 3, 2017
• Grant date: Aug 31, 2021
• Expiry date: Oct 3, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.